ALFA Finder| Value | ₹15.00 Cr |
|---|
BSE filing, NSE: SAIPARENT. Summary written from the filing by ALFA Finder's alert engine.
Sai Parenterals Ltd: key numbers
- Share price
- ₹466.35
- Market cap
- ₹2,060 Cr
- Revenue (annual)
- ₹381.0 Cr
- Net profit (annual)
- ₹14.26 Cr
- P/E (TTM)
- 82.7×Sector 43.0×
- Promoter holding
- 51.16%+0.00% QoQ
- FII holding
- 2.85%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sai Parenterals Ltd
All →Sai Parenterals Earnings Call Transcript: Key Takeaways
Sai Parenterals is transitioning from a standalone unit to a consolidated manufacturing and R&D powerhouse through strategic acquisitions. While revenue grew 9% sequentially, high depreciation from new assets is currently masking operating profitability gains.
Sai Parenterals Other Announcement
Sai Parenterals filed its quarterly shareholding pattern for the quarter ended 30 September 2026. Promoters and promoter group hold 51.16 per cent.
Sai Parenterals Investor Presentation: Key Takeaways
Q2/H1 FY27 deck (Sep 2026) gives no quarterly P&L figures. Highlights: 302 products, 599 registrations, FY26 export share 63%, Saicriti injectable and Noumed acquisitions.
Sai Parenterals Results Update
Sai Parenterals reported Q2FY27 consolidated revenue of Rs. 196 crore and PAT of Rs. 11 crore. Gross margin improved to 47.5%.
Sai Parenterals Acquisition
Sai Parenterals will acquire the remaining 25% stake in its 75% subsidiary SP Analytics for cash, making it wholly owned. Related-party approval was taken at the 1 November 2026 board meeting, with completion by 31 December 2026.
- Execution
- 31-12-2026
Sai Parenterals Q2 FY27 Results: Net Profit ₹10.5 Cr, Up 66.7% YoY
Sai Parenterals Ltd reported revenue from operations of ₹194.9 Cr (+264.3% YoY) and net profit of ₹10.5 Cr (+66.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹10.5 Cr · +66.7% YoY
Other merger & restructuring announcements
All →AAA Technologies Merger & Restructuring
AAA Technologies approved four wholly owned subsidiaries in Singapore, Mauritius, Dubai and India. Each entity is in IT security, cybersecurity and technology services.
Tirupati Starch & Chemicals Merger & Restructuring Worth ₹2.98 Cr
Tirupati Starch agreed to sell its Indore immovable property to Usha and Arpit Doshi for Rs 2.98 Crore. Completion is expected by 15 January 2027, subject to conditions.
- Value
- ₹2.98 Cr
- Execution
- Completion expected on or before 15 January 2027
CFF Fluid Control Merger & Restructuring
CFF Fluid Control will form a 51% joint venture with TKMS Atlas Elektronik for anti-submarine warfare in India. No deal value is disclosed.
Trom Industries Merger & Restructuring Worth ₹0.02 Cr
Trom Industries plans to incorporate Trom Energy SPV Private Limited, a solar power subsidiary, holding 98%. The initial cash subscription is Rs 1,96,000 for 19,600 shares.
- Value
- ₹0.02 Cr
Yasons Chemex Care Merger & Restructuring Worth ₹29.61 Cr
Yasons Chemex's subsidiary Rishit Polysurf LLP signed a slump sale agreement to sell its chemical manufacturing business to Vasudha Specialities Emulsifiers. Consideration is Rs.29.61 Crore in cash.
- Value
- ₹29.61 Cr
Dhruv Consultancy Services Merger & Restructuring Worth ₹0.3 Cr
Dhruv Consultancy incorporated Valsang Drivehub Private Limited, subscribing to 55% for Rs.0.30 Crore. The subsidiary will execute a wayside amenities project under an NHLML award.
- Value
- ₹0.30 Cr